China’s India Headache: The growing pharmaceutical industry

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desire to diversify from China. These companies are investing in advanced technologies and specialized capabilities, particularly in biologics and complex chemistry, to capture a larger share of the global market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hSyN8pX
via IFTTT